“BREAKING: First Alzheimer’s commercial blood test to detect amyloid beta hits the market,” by Alicia Lasek, McKnight’s LTC News
Quote: “A new blood test that detects the likelihood that a patient has Alzheimer’s brain plaques on Thursday became the first to hit the commercial market. The PrecivityAD test is performed using a small blood sample taken in a clinical setting which is then processed in the test developer’s lab. It detects the presence of amyloid beta biomarkers, helping to predict the likely results of a diagnostic brain scan, the company said in a statement.”
LTC Comment: Whether you want to know or not your insurer will. So get the LTCI policy now so when the blood test is done sometime in the future you’re already covered.